Drug intelligence / Profile preview

isoproterenol

Development stage
Approved
Modality
Small Molecules
Administration
Inhalation, Intravenous, Intramuscular, Subcutaneous, Sublingual
01

Overview

Isoproterenol (also known as isoprenaline) is a synthetic non-selective beta adrenergic agonist and catecholamine. It acts primarily by stimulating beta1 and beta2 adrenergic receptors, leading to increased heart rate, enhanced cardiac contractility, and bronchodilation. Its main clinical uses include the treatment of bradycardia, heart block, Adams-Stokes syndrome, bronchospasm during anesthesia, acute asthma attacks, certain types of cardiac arrhythmias, acute exacerbations of COPD, and shock. Isoproterenol was developed in the mid-twentieth century as a sympathomimetic agent structurally related to epinephrine but with greater selectivity for beta receptors[1][2][3][8][10].

Brand names
IsuprelIsuprel MistometerMedihaler-IsoProternol LSaventrineAeroloneAerotrolVapo-Iso
Other names
isopropydrinasiprenolassiprenolbellasthmanisoprenalinrespifralaludrineasmalarneodrenalneo-Epinineisopropylarterenolisonorinlomupren
02

Targets

ADRB2 (β2)ADRB1 (β1)

Beyond the preview

Go deeper on isoproterenol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isoproterenol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call